1. Home
  2. WOOF vs ANL Comparison

WOOF vs ANL Comparison

Compare WOOF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Petco Health and Wellness Company Inc.

WOOF

Petco Health and Wellness Company Inc.

HOLD

Current Price

$2.70

Market Cap

762.1M

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$13.82

Market Cap

611.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WOOF
ANL
Founded
1965
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
762.1M
611.1M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
WOOF
ANL
Price
$2.70
$13.82
Analyst Decision
Hold
Strong Buy
Analyst Count
9
1
Target Price
$4.06
$20.00
AVG Volume (30 Days)
1.4M
148.1K
Earning Date
06-04-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
108.11
N/A
EPS
N/A
N/A
Revenue
$5,961,467,000.00
N/A
Revenue This Year
$2.64
$36.02
Revenue Next Year
$1.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.24
$0.88
52 Week High
$3.96
$17.25

Technical Indicators

Market Signals
Indicator
WOOF
ANL
Relative Strength Index (RSI) 48.73 55.96
Support Level $2.70 $12.45
Resistance Level $2.80 $15.32
Average True Range (ATR) 0.11 0.94
MACD -0.01 0.00
Stochastic Oscillator 28.72 56.99

Price Performance

Historical Comparison
WOOF
ANL

About WOOF Petco Health and Wellness Company Inc.

Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: